J&J Ponders Elan Tie While Alzheimer Drug Future Reviewed

Johnson & Johnson hasn’t given up on the ability of its experimental drug bapineuzumab to alter the course of Alzheimer’s disease, even after two key studies failed to find a benefit, the company’s neuroscience unit head said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.